Bio-Rad Laboratories is driving innovation in oncology diagnostics with its Droplet Digital PCR (ddPCR) technology, making it easier for contract testing laboratories to deliver sensitive and reliable results for cancer monitoring. Recent updates include the IVDR Class C certification for the QXDx BCR-ABL %IS Kit and an expanded library of methylation detection assays.
Benefits for contract testing laboratories
- Regulatory Compliance: The IVDR-certified QXDx BCR-ABL %IS Kit meets stringent European standards, providing a reliable tool for leukemia monitoring.
- Diverse Testing Capabilities: Over 50 new ddPCR assays enable contract labs to expand their offerings in methylation detection and oncology diagnostics.
- Unmatched Precision: The QX600 ddPCR System ensures accurate and early detection of cancer biomarkers, including ctDNA.
- Collaborative Insights: Partnerships with Biodesix and Aarhus University Hospital provide valuable frameworks for developing MRD testing protocols.
These advancements position Bio-Rad as a trusted partner for contract testing labs aiming to deliver cutting-edge oncology diagnostics and support collaborative research initiatives.
This article is an AI generated summary of a published press release provided by Bio-Rad
